Investigational drug · Phase 3
BNC210
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Social Anxiety Disorder.
Phase 3Last checked: Nov 19, 2026Latest source record: May 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "BNC210"
First trial start
2024
Aug 6, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BNC210", any sponsor or status.
Conditions studied
As listed on its trial records.
- Social Anxiety Disorder
Approved drugs for the same conditions: Anxiety disorders · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "BNC210" as an intervention, largest first.
- Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1Pivotal-lookingCompleted
Bionomics LimitedIndustry
NCT06510504 · 370 participants · Start Aug 6, 2024 · Primary completion Sep 11, 2025
Drug: 225 mg BNC210; Placebo · For: Social Anxiety Disorder
Sites: Encino, California; La Jolla, California; Los Angeles, California · 21 sites in all
- A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)Pivotal-lookingCompleted
Bionomics LimitedIndustry
NCT04951076 · 212 participants · Start Jul 27, 2021 · Primary completion Jul 25, 2023
Drug: BNC210; Placebo · For: Post-Traumatic Stress Disorder
Sites: Bellflower, California; Beverly Hills, California; Colton, California · 32 sites in all
- Phase II Study of BNC210 in PTSDPivotal-lookingCompleted
Bionomics LimitedIndustry
NCT02933606 · 193 participants · Start Jun 30, 2016 · Primary completion Jul 5, 2018
Drug: BNC210; Placebo · For: Post-Traumatic Stress Disorder
Sites: Oceanside, California; Rancho Mirage, California; Redlands, California · 25 sites in all
- A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety DisorderPivotal-lookingCompleted
Bionomics LimitedIndustry
NCT05193409 · 151 participants · Start Feb 2, 2022 · Primary completion Oct 10, 2022
Drug: 225 mg BNC210; 675 mg BNC210 and 1 more · For: Social Anxiety Disorder
Sites: Beverly Hills, California; Encino, California; Glendale, California · 15 sites in all
Bionomics LimitedIndustry
NCT03548194 · 38 participants · Start May 17, 2018 · Primary completion Apr 23, 2019
Drug: BNC210; Placebo · For: Agitation in the Elderly
Sites: Sydney, Australia; Adelaide, Australia; Melbourne, Australia · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The Pathway to Proof-of-Concept for BNC210, a Negative Allosteric Modulator of the Alpha-7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease.
Rolan P, Doolin E, Paul D, et al. · Clin Pharmacol Drug Dev 2026
- A phase 2, placebo-controlled study to evaluate the efficacy and safety of BNC210, an alpha-7 nicotinic receptor negative allosteric modulator, for acute, as-needed treatment of social anxiety disorder (SAD) - The PREVAIL study.
Papapetropoulos S, Doolin E, Odontiadis M, et al. · Psychiatry Res 2025
- BNC210, an α7 Nicotinic Receptor Modulator, in Post-Traumatic Stress Disorder.
Papapetropoulos S, Doolin E, O'Connor S, et al. · NEJM Evid 2025
- BNC210, a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor, demonstrates anxiolytic- and antidepressant-like effects in rodents.
O'Connor SM, Sleebs BE, Street IP, et al. · Neuropharmacology 2024
- A Neuroanatomic and Pathophysiologic Framework for Novel Pharmacological Approaches to the Treatment of Post-traumatic Stress Disorder.
Norred MA, Zuschlag ZD, Hamner MB · Drugs 2024
- BNC210: an investigational α7-nicotinic acetylcholine receptor modulator for the treatment of anxiety disorders.
Hampsey E, Perkins A, Young AH · Expert Opin Investig Drugs 2023
Also in development for Social Anxiety Disorder
- FasedienolPhase 32 trials
VistaGen Therapeutics, Inc. · Social Anxiety Disorder, Social Anxiety Disorder (SAD)
- EMP-01Phase 21 trial
atai Therapeutics, Inc. · Social Anxiety Disorder
- RGH-202Phase 21 trial
Gedeon Richter Plc. · Social Anxiety Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.